 |
|
|
| |
FEASIBILITY, EFFICACY, AND SAFETY OF USING DOLUTEGRAVIR/LAMIVUDINE (DTG/3TC) AS A FIRST-LINE REGIMEN IN A TEST-AND-TREAT SETTING FOR NEWLY DIAGNOSED PEOPLE LIVING WITH HIV (PLWH): THE STAT STUDY
|
| |
| |
Glasgow 2020 Oct 5-8 virtual
Reported by Jules Levin
Charlotte-Paige Rolle,1 Mezgebe Berhe,2 Tulika Singh,3 Roberto Ortiz,4 Anson Wurapa,5 Moti Ramgopal,6 Peter A. Leone,7 Jessica E. Matthews,7 Marybeth Dalessandro,8 Mark R. Underwood,7 Konstantinos Angelis,9 Brian R. Wynne,7 Deanna Merrill,7 Christopher Nguyen,7 Jean van Wyk10
1Orlando Immunology Center, Orlando, FL, USA; 2Baylor University Medical Center, Dallas, TX, USA; 3Desert AIDS Project, Palm Springs, CA, USA; 4Bliss Healthcare Services,
Orlando, FL, USA; 5Infectious Disease Specialists of Atlanta, Decatur, GA, USA; 6Midway Immunology and Research Center, Fort Pierce, FL, USA; 7ViiV Healthcare,
Research Triangle Park, NC, USA; 8GlaxoSmithKline, Upper Providence, PA, USA; 9GlaxoSmithKline, Uxbridge, UK; 10ViiV Healthcare, Brentford, UK
|
| |
|
|
|
|
|
